Role of residual renal function in phosphate control and anemia management in chronic hemodialysis patients

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 2, 2011, Pages 281-289

  Penne, E Lars ^a,b   Van Der Weerd, Neelke C ^a,b   Grooteman, Muriel P C ^b   Mazairac, Albert H A ^a   Van Den Dorpel, Marinus A ^c   Nube, Menso J ^b   Bots, Michiel L ^a   Lévesque, Renée ^d   Ter Wee, Piet M ^b   Blankestijn, Peter J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Maasstad Hospital Rotterdam   (Netherlands)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; CALCIUM ACETATE; CALCIUM CARBONATE; CALCIUM LACTOGLUCONATE; LANTHANUM CARBONATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PHOSPHATE; PHOSPHATE BINDING AGENT; RECOMBINANT ERYTHROPOIETIN; SEVELAMER;

ADULT; ANEMIA; ANURIA; ARTICLE; FEMALE; GLOMERULUS FILTRATION RATE; HEMATOCRIT; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; RESIDUAL RENAL FUNCTION;

AGED; ANEMIA; ANURIA; BIOLOGICAL MARKERS; CANADA; CHI-SQUARE DISTRIBUTION; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HEMATINICS; HEMATOCRIT; HEMOGLOBINS; HUMANS; KIDNEY; KIDNEY DISEASES; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; NETHERLANDS; PHOSPHATES; PROSPECTIVE STUDIES; RENAL DIALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79951865856     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04480510     Document Type: Article

References (50)

1. Wang AY, Lai KN: The importance of residual renal function in dialysis patients. Kidney Int 69: 1726-1732, 2006 (Pubitemid 43739198)
2. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y: Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int 64: 2238-2243, 2003 (Pubitemid 37449560)
3. Morduchowicz G, Winkler J, Zabludowski JR, Boner G: Effects of residual renal function in haemodialysis patients. Int Urol Nephrol 26: 125-131, 1994 (Pubitemid 24151942)
4. Wang AY, Woo J, Sea MM, Law MC, Lui SF, Li PK: Hyperphosphatemia in Chinese peritoneal dialysis patients with and without residual kidney function: What are the implications? Am J Kidney Dis 43: 712-720, 2004 (Pubitemid 38401887)
5. Lopez-Menchero R, Miguel A, Garcia-Ramon R, Perez-Contreras J, Girbes V: Importance of residual renal function in continuous ambulatory peritoneal dialysis: Its influence on different parameters of renal replacement treatment. Nephron 83: 219-225, 1999 (Pubitemid 29486400)
6. Cheung AK, Rocco MV, Yan G, Leypoldt JK, Levin NW, Greene T, Agodoa L, Bailey J, Beck GJ, Clark W, Levey AS, Ornt DB, Schulman G, Schwab S, Teehan B, Eknoyan G: Serum beta-2 microglobulin levels predict mortality in dialysis patients: Results of the HEMO study. J Am Soc Nephrol 17: 546-555, 2006
7. McCarthy JT, Williams AW, Johnson WJ: Serum beta 2-microglobulin concentration in dialysis patients: Importance of intrinsic renal function. J Lab Clin Med 123: 495-505, 1994 (Pubitemid 2083546)
8. Szeto CC, Lai KN, Wong TY, Law MC, Leung CB, Yu AW, Li PK: Independent effects of residual renal function and dialysis adequacy on nutritional status and patient outcome in continuous ambulatory peritoneal dialysis. Am J Kidney Dis 34: 1056-1064, 1999
9. Merkus MP, Jager KJ, Dekker FW, Boeschoten EW, Stevens P, Krediet RT: Quality of life in patients on chronic dialysis: Self-assessment 3 months after the start of treatment. The Necosad Study Group. Am J Kidney Dis 29: 584-592, 1997 (Pubitemid 27155281)
10. Wang AY, Wang M, Woo J, Law MC, Chow KM, Li PK, Lui SF, Sanderson JE: A novel association between residual renal function and left ventricular hypertrophy in peritoneal dialysis patients. Kidney Int 62: 639-647, 2002 (Pubitemid 34779779)
11. Wang AY, Wang M, Woo J, Lam CW, Lui SF, Li PK, Sanderson JE: Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol 15: 2186-2194, 2004 (Pubitemid 39031357)
12. Bargman JM, Thorpe KE, Churchill DN: Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: A reanalysis of the CANUSA study. J Am Soc Nephrol 12: 2158-2162, 2001 (Pubitemid 32880353)
13. Termorshuizen F, Dekker FW, van Manen JG, Korevaar JC, Boeschoten EW, Krediet RT: Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: An analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol 15: 1061-1070, 2004 (Pubitemid 38375326)
14. Bragg-Gresham JL, Fissell RB, Mason NA, Bailie GR, Gillespie BW, Wizemann V, Cruz JM, Akiba T, Kurokawa K, Ramirez S, Young EW: Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS). Am J Kidney Dis 49: 426-431, 2007
15. Vilar E, Wellsted D, Chandna SM, Greenwood RN, Farrington K: Residual renal function improves outcome in incremental haemodialysis despite reduced dialysis dose. Nephrol Dial Transplant 24: 2502-2510, 2009
16. Shafi T, Jaar BG, Plantinga LC, Fink NE, Sadler JH, Parekh RS, Powe NR, Coresh J: Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: The Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) study. Am J Kidney Dis 56: 348-358, 2010
17. Schiffl H, Lang SM, Fischer R: Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. Nephrol Dial Transplant 17: 1814-1818, 2002
18. McKane W, Chandna SM, Tattersall JE, Greenwood RN, Farrington K: Identical decline of residual renal function in high-flux biocompatible hemodialysis and CAPD. Kidney Int 61: 256-265, 2002 (Pubitemid 34075153)
19. Noordzij M, Voormolen NM, Boeschoten EW, Dekker FW, Bos WJ, Krediet RT, Korevaar JC: Disordered mineral metabolism is not a risk factor for loss of residual renal function in dialysis patients. Nephrol Dial Transplant 24: 1580-1587, 2009
20. Penne EL, Blankestijn PJ, Bots ML, van den Dorpel MA, Grooteman MP, Nube MJ, van der Tweel I, ter Wee PM: Effect of increased convective clearance by on-line hemodiafiltration on all cause and cardiovascular mortality in chronic hemodialysis patients - The Dutch CONvective TRAnsport STudy (CONTRAST): Rationale and design of a randomised controlled trial [ISRCTN38365125]. Curr Control Trials Cardiovasc Med 6: 8, 2005
21. Clase CM, St Pierre MW, Churchill DN: Conversion between bromcresol green- and bromcresol purple-measured albumin in renal disease. Nephrol Dial Transplant 16: 1925-1929, 2001
22. KDOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 42[Suppl 3]: S1-S201, 2003
23. Fouque D, Vennegoor M, ter WP, Wanner C, Basci A, Canaud B, Haage P, Konner K, Kooman J, Martin-Malo A, Pedrini L, Pizzarelli F, Tattersall J, Tordoir J, Vanholder R: EBPG guideline on nutrition. Nephrol Dial Transplant 22[Suppl 2]: ii45-ii87, 2007
24. Daugirdas JT: Second generation logarithmic estimates of single-pool variable volume Kt/V: An analysis of error. J Am Soc Nephrol 4: 1205-1213, 1993
25. Depner TA, Daugirdas JT: Equations for normalized protein catabolic rate based on two-point modeling of hemodialysis urea kinetics. J Am Soc Nephrol 7: 780-785, 1996 (Pubitemid 27466012)
26. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47[Suppl 3]: S11-S145, 2006
27. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK: Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 52: 519-530, 2008
28. Slinin Y, Foley RN, Collins AJ: Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: The USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 16: 1788-1793, 2005 (Pubitemid 41716485)
29. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218, 2004 (Pubitemid 39031360)
30. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM: Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 39: 695-701, 2002 (Pubitemid 34158168)
31. Young EW, Akiba T, Albert JM, McCarthy JT, Kerr PG, Mendelssohn DC, Jadoul M: Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 44: 34-38, 2004
32. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl Aug: S1-S130, 2009
33. Lopez-Gomez JM, Portoles JM, Aljama P: Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. Kidney Int Suppl Dec: S75-S81, 2008
34. Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ: Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 44: 866-876, 2004 (Pubitemid 39445919)
35. Kaysen GA, Muller HG, Ding J, Chertow GM: Challenging the validity of the EPO index. Am J Kidney Dis 47: 166, 2006
36. Agarwal R, Davis JL, Smith L: Serum albumin is strongly associated with erythropoietin sensitivity in hemodialysis patients. Clin J Am Soc Nephrol 3: 98-104, 2008
37. Gaweda AE, Goldsmith LJ, Brier ME, Aronoff GR: Iron, inflammation, dialysis adequacy, nutritional status, and hyperparathyroidism modify erythropoietic response. Clin J Am Soc Nephrol 5: 576-581, 2010
38. Kalantar-Zadeh K, Lee GH, Miller JE, Streja E, Jing J, Robertson JA, Kovesdy CP: Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis 53: 823-834, 2009
39. Movilli E, Cancarini GC, Vizzardi V, Camerini C, Brunori G, Cassamali S, Maiorca R: Epoetin requirement does not depend on dialysis dose when Kt/N > 1.33 in patients on regular dialysis treatment with cellulosic membranes and adequate iron stores. J Nephrol 16: 546-551, 2003 (Pubitemid 38120464)
40. Kamper AL, Nielsen OJ: Effect of enalapril on haemoglobin and serum erythropoietin in patients with chronic nephropathy. Scand J Clin Lab Invest 50: 611-618, 1990
41. Mohanram A, Zhang Z, Shahinfar S, Lyle PA, Toto RD: The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes. Kidney Int 73: 630-636, 2008 (Pubitemid 351264116)
42. Saudan P, Halabi G, Perneger T, Wasserfallen JB, Wauters JP, Martin PY: ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance. J Nephrol 19: 91-96, 2006
43. Abu-Alfa AK, Cruz D, Perazella MA, Mahnensmith RL, Simon D, Bia MJ: ACE inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients. Am J Kidney Dis 35: 1076-1082, 2000 (Pubitemid 30354410)
44. Rossert J, Gassmann-Mayer C, Frei D, McClellan W: Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Nephrol Dial Transplant 22: 794-800, 2007 (Pubitemid 46351687)
45. Macdougall IC: Role of uremic toxins in exacerbating anemia in renal failure. Kidney Int Suppl 78: S67-S72, 2001
46. Drueke TB, Eckardt KU: Role of secondary hyperparathyroidism in erythropoietin resistance of chronic renal failure patients. Nephrol Dial Transplant 17[Suppl 5]: 28-31, 2002 (Pubitemid 34823069)
47. Pecoits-Filho R, Heimburger O, Barany P, Suliman M, Fehrman-Ekholm I, Lindholm B, Stenvinkel P: Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 41: 1212-1218, 2003 (Pubitemid 36637976)
48. Ignace S, Fouque D, Arkouche W, Steghens JP, Guebre- Egziabher F: Preserved residual renal function is associated with lower oxidative stress in peritoneal dialysis patients. Nephrol Dial Transplant 24: 1685-1689, 2009
49. Kabanda A, Jadoul M, Pochet JM, Lauwerys R, van Ypersele de Strihou C, Bernard A: Determinants of the serum concentrations of low molecular weight proteins in patients on maintenance hemodialysis. Kidney Int 45: 1689-1696, 1994 (Pubitemid 24207505)
50. Penne EL, van der Weerd NC, Blankestijn PJ, van den Dorpel MA, Grooteman MP, Nube MJ, ter Wee PM, Levesque R, Bots ML: Role of residual kidney function and convective volume on change in beta2-microglobulin levels in hemodiafiltration patients. Clin J Am Soc Nephrol 5: 80-86, 2010